$1.46
-0.09-5.81%
At close: Feb 10, 4:00 PM EST
$1.39
-0.16-10.15%
Pre-Market: 4:00 AM EST
Comments
Loading...
Marker Therapeutics Inc Analyst Ratings
MRKRNASDAQ
Marker Therapeutics Analyst Ratings and Price Targets | NASDAQ:MRKR | Benzinga
Marker Therapeutics Inc has a consensus price target of $12.38 based on the ratings of 4 analysts. The high is $19 issued by Ladenburg Thalmann on October 21, 2024. The low is $8 issued by Canaccord Genuity on March 5, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., WBB Securities, and Canaccord Genuity on December 8, 2025, April 1, 2025, and March 5, 2025, respectively. With an average price target of $10.17 between HC Wainwright & Co., WBB Securities, and Canaccord Genuity, there's an implied 630.05% upside for Marker Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
WBB Securities
Canaccord Genuity
Ladenburg Thalmann
1calculated from analyst ratings
Analyst Ratings for Marker Therapeutics
FAQ
What is the target price for Marker Therapeutics (MRKR) stock?
The latest price target for Marker Therapeutics (NASDAQ:MRKR) was reported by HC Wainwright & Co. on December 8, 2025. The analyst firm set a price target for $10.00 expecting MRKR to rise to within 12 months (a possible 618.08% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Marker Therapeutics (MRKR)?
The latest analyst rating for Marker Therapeutics (NASDAQ:MRKR) was provided by HC Wainwright & Co., and Marker Therapeutics initiated their buy rating.
When was the last upgrade for Marker Therapeutics (MRKR)?
There is no last upgrade for Marker Therapeutics
When was the last downgrade for Marker Therapeutics (MRKR)?
There is no last downgrade for Marker Therapeutics.
When is the next analyst rating going to be posted or updated for Marker Therapeutics (MRKR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marker Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marker Therapeutics was filed on December 8, 2025 so you should expect the next rating to be made available sometime around December 8, 2026.
Is the Analyst Rating Marker Therapeutics (MRKR) correct?
While ratings are subjective and will change, the latest Marker Therapeutics (MRKR) rating was a initiated with a price target of $0.00 to $10.00. The current price Marker Therapeutics (MRKR) is trading at is $1.39, which is within the analyst’s predicted range.
